Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23022399 | 1.00 | MEN1 (0.39) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL23022398 | 1.00 | MEN1 (0.39) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL23774428 | 0.79 | MEN1 (0.41) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL22242704 | 0.75 | — | — | |
| SCHEMBL232681 | 0.75 | — | — | |
| SCHEMBL22553564 | 0.75 | — | — | |
| SCHEMBL10188216 | 0.71 | MEN1 (0.37) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL29348150 | 0.71 | MEN1 (0.37) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL23047553 | 0.71 | MEN1 (0.32) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL21626527 | 0.70 | MEN1 (0.35) | MEN1CYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053989-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | PTPN11, PPM1F, PTPRF | MEN1 2450/4885CYP1A2 4226/4885CYP3A4 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.